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a blueprint for action

rojections by a research group led by who and
unaids, published in The Lancet in July 2002,
indicate that the global hiv infection rate will
continue its rapid pace, producing 45 million new
infections between 2002 and 2010. The analysis also
states that this scenario is in no way inevitable. In fact, 
28 million (63 percent) of these new infections could 
be prevented if existing hiv prevention strategies are
substantially scaled up,1 and even more could be averted
with the advent of new prevention technologies. 
The Global hiv Prevention Working Group—
composed of leading experts in public health, clinical
care, biomedical, behavioral, and social research, and
people affected by hiv/aids, and convened by the Bill &
Melinda Gates Foundation and the Henry J. Kaiser
Family Foundation—seeks to generate a greatly expanded
commitment to preventing hiv transmission as part of a
comprehensive approach to fighting the global epidemic. 
The world knows much about how to prevent hiv
transmission, and both developed and developing coun-
tries have demonstrated that existing prevention strategies
can have a major impact. This “blueprint for action”—the
first report of the Working Group—provides a road map
for rapidly scaling up prevention programs to contain and
ultimately reverse the aids epidemic. The report reviews
the scientific literature on the effectiveness of hiv preven-
tion interventions, identifies obstacles to quickly expanding
prevention programs, and makes specific recommenda-
tions to prevent millions of infections this decade.
challenging the
sense of inevitability
While hiv/aids has prompted much compassion and
concern, the global community often behaves as if a
massive expansion of hiv/aids were inevitable, as if the
world has little choice but to watch anxiously and hope
that the epidemic eventually burns itself out. This sense
of inevitability ignores not only the extraordinary
resources at the world’s disposal but also the fact that our
knowledge of effective prevention strategies has grown
substantially in recent years. 
Today, prevention efforts reach fewer than 1 in 5 of
those at risk.2 To have an impact on the future course 
of the epidemic, pilot prevention projects must rapidly
become comprehensive programs that reach all those 
at risk, and obstacles to prevention must be swiftly
addressed and overcome. 
With the immense resources at its disposal, will the
world respond to this growing crisis? Having failed to
prevent the first wave of the epidemic, will we have the




hiv prevention has proven remarkably effective in 
developed and developing countries, for all populations at
risk, and in both emerging and mature epidemics. hiv
prevention strategies are also extraordinarily cost-effective,
helping countries, especially those with limited resources,
avoid the future costs of countless new hiv infections.
Extensive scientific research has identified effective
prevention interventions for all routes of hiv transmission: 
Sexual Transmission. The risk of sexual transmission 
of hiv can be reduced through a wide range of proven
interventions: behavior change programs that encourage
people to delay initiation of sex or reduce their number of
partners; condom promotion; prevention and treatment
of sexually transmitted diseases; and expansion of volun-
tary counseling and testing. These interventions have
been shown to be effective in a wide range of popula-
tions, including young people, heterosexual adults, and
men who have sex with men. 
Parenteral Transmission. Parenteral transmission of hiv
can be prevented through implementation of policies to
protect blood supplies and to promote safety in health




gies to reduce the risk of infection through injection drug
use, such as methadone maintenance and other drug
treatment programs, peer outreach, and syringe and
needle programs.
Mother-to-Child Transmission. The risk of mother-to-child
hiv transmission can be reduced by half or more with
short courses of antiretroviral drugs, voluntary counseling
and testing, and enhanced reproductive health services.
Effective hiv prevention involves a carefully planned
combination of these interventions, reinforced by public
policies to combat the social factors that facilitate hiv
transmission. Just as combination antiretroviral therapy
slows hiv replication by attacking the virus from
multiple angles, effective prevention strategies must be
integrated to address the many behavioral and biomed-
ical susceptibilities of individuals and communities. 
obstacles to scaling
up hiv prevention
Given the overwhelming evidence demonstrating what
works to prevent hiv transmission, the biggest challenge
is to scale up effective prevention models to reach millions
more people at risk. A number of obstacles stand in the
way of bringing prevention programs to scale: 
Resources. Ninety-five percent of hiv infections occur in
developing countries, where resources are most limited.3
unaids projects that $4.8 billion annually is needed to
mount a comprehensive global effort to prevent new
infections in low and middle-income countries,4 yet
current global spending for prevention programs in these
countries amounts to only about $1.2 billion each year.5
As a result, prevention programs have not achieved the
depth and breadth needed to have a large-scale impact on
the epidemic.
Earlier calls for increased resources for hiv prevention
went unheeded. In 1993, the who Global Programme on
aids projected that an investment of $1.5 billion to $2.9
billion annually could prevent half of all projected infec-
tions in 2000 and save $90 billion in associated costs.6
Having failed to commit these resources, the world now
confronts not only an expanding epidemic, but also esca-
lating costs for both hiv prevention and treatment. 
Capacity. An effective global prevention effort will need to
build local capacity in developing countries to sustain a
long-term, high-level effort to prevent new infections. 
Stigma. The stigma associated both with hiv/aids and
with the groups often at highest risk must be boldly
attacked—through strong political leadership, enactment
of meaningful legal protections, and the active engage-
ment of people living with hiv/aids.
Political Commitment. In every country where hiv
prevention efforts have succeeded, strong political
commitment has been a critical element of success.
Although many political leaders are more willing than
ever to voice strong support for the fight against hiv/aids,
the level of political leadership is still inadequate, espe-
cially in many countries with emerging epidemics. 
Treatment Access. As the world mounts a comprehensive
effort to prevent new infections, access to hiv treatments
in developing countries must also significantly increase.
Treatment is not only a humanitarian imperative—
improved access to treatment can support hiv prevention
by encouraging early knowledge of hiv status and
reducing the stigma associated with the disease. 
New Technologies. While the world brings to scale every
available prevention strategy, it must also accelerate the
search for a preventive vaccine, for an effective microbi-
cide, and for other barrier methods and technologies that
reduce the likelihood of transmission. 
summary of 
recommendations
To expand hiv prevention to reach all those at risk, 
and help prevent millions of new infections this decade,
the Global hiv Prevention Working Group makes the
following recommendations:
Substantially Increase and Sustain Prevention
Funding
t Increase international resources. Annual investment
in hiv prevention in low- and middle-income coun-
tries should quadruple by 2004—from approximately
$1.2 billion today to $4.8 billion, as called for by
unaids. Annual funding must be sustained at this
level through 2010 and well into the next decade. 
t Enable countries to prioritize resources for hiv/aids.
Every effort should be made to give countries the ability
to prioritize resources for hiv/aids, especially resource-
poor countries financially encumbered by debt. 
2
3Build Capacity and Scale Up Proven Prevention
Strategies 
t Increase local capacity. Resources should be devoted to
training local personnel and providing necessary tech-
nology so that affected countries can rapidly and
sustainably scale up prevention programs. 
t Expand existing prevention strategies. With additional
resources and access to training and prevention tools,
countries should rapidly bring to scale key prevention
interventions that can work together to achieve maxi-
mum prevention impact. In particular, countries should
scale up voluntary counseling and testing; mass media
campaigns; condom distribution, promotion and social
marketing; blood screening; school-based programs;
programs for out-of-school youth; workplace programs;
std treatment; and peer counselors for vulnerable popu-
lations, such as sex workers, men who have sex with
men (msm), and injection drug users (idus). 
t Focus on vulnerable populations. Particularly high
priority should be given to scale-up of programs to
prevent transmission in vulnerable populations,
including young people, sex workers, msm, and idus.
Encourage Vocal Political Leadership
t Make hiv/aids a priority. Political leaders should speak
often and forcefully about the importance of hiv preven-
tion, support policies that effectively fight aids and
stigma, and make hiv/aids a permanent agenda item at
important global and regional political gatherings.
Use Prevention Resources More Strategically 
t Improve tracking of hiv/aids. Developing countries
should receive training and financial and technical
assistance to enhance their ability to track hiv/aids
and plan prevention interventions accordingly. 
t Ensure strategic planning. By 2003, every country
should have a strategic hiv prevention plan. 
t Coordinate funds. By 2003, every low-income country
should convene annual “donor roundtables,” bringing
together all key funders to measure available
resources, identify resource gaps, and enhance
program coordination. 
Expand Access To Key Prevention Tools
t Ensure adequate supply of prevention tools. Donor
nations should ensure an adequate global supply of
high-quality hiv prevention tools (e.g., condoms and
hiv test kits) for use in developing countries.
t Increase access to treatment. Access to hiv treatments,
including arvs, should be dramatically expanded—
both to reduce hiv-related sickness and death and to
buttress hiv prevention efforts by reducing stigma and
encouraging knowledge of hiv status. 
Accelerate Research Into New Prevention 
Technologies
t Increase funding. Public sector funding for research
and development should increase by $1 billion for
hiv/aids vaccines and by $1 billion for microbicides by
2007. Substantial new funding is also needed for inves-
tigation of female-controlled barrier methods and other
new technologies to reduce the risk of transmission. 
t Provide private sector incentives. Donor nations
should provide financial incentives to private compa-
nies to increase their investment in research and
development related to hiv/aids vaccines, microbi-
cides, and other new prevention technologies. 
t Coordinate efforts. Industry, donors, multilateral agen-
cies, and ngos should work together on an ongoing
basis to identify obstacles to acceleration of hiv
vaccine and microbicide r&d, and agree on approaches
to overcoming such obstacles. 
t Ensure access. Donor nations, developing countries,
and multilateral agencies should immediately develop
and implement strategies to ensure future access to
hiv/aids vaccines and microbicides. 
Confront Social Factors that Facilitate the 
Spread of hiv
t Fight stigma. Countries should enact hiv-specific
human rights protections and implement anti-stigma
strategies targeting groups vulnerable to hiv/aids,
especially injection drug users, men who have sex with
men, and people with multiple sex partners (e.g., sex
workers). People living with hiv/aids should be
involved at every stage in planning and implementing
hiv prevention programs.
t Reduce poverty. Accelerated efforts are needed to
reduce the poverty that facilitates hiv transmission
and worsens the social and economic impact of hiv
infection. 
t Empower women. Global efforts to increase the
economic, legal, political and social empowerment of
women should be substantially expanded to decrease
their vulnerability to hiv.
s hiv continues its relentless spread throughout
the globe, the fate of millions and the future 
of nations hang in the balance. Projections 
by a research group led by who and unaids,
published in The Lancet in July 2002, indicate that the
global hiv infection rate will continue its rapid pace,
producing 45 million new infections between 2002 
and 2010.7
Conservative projections suggest that well over 2
million people in Russia will be infected by 2010 in the
absence of effective prevention.8
In sub-Saharan Africa, where aids has already erased
decades of health gains, infection rates continue to rise
beyond levels previously thought possible, threatening
yet another generation in the world’s most impoverished
region.
China and India, home to a third of the world’s 
population, stand on the precipice of a potential aids
catastrophe, as infection migrates from discrete high-risk
groups to the broader population.
The importance of immediate mobilization to prevent
an acute worsening of the global epidemic is underscored
by the experience in South Africa. In a mere decade, hiv
prevalence among pregnant women there skyrocketed
from less than one percent to 25 percent today.
aids has awakened the world to intolerable global
inequities. While medical advances have sharply reduced
hiv-related death and sickness in industrialized coun-
tries, the epidemic continues on as before in developing
countries, harming families, burdening the most vulner-
able, and robbing entire regions of hope for the future.
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GLOBAL ESTIMATES OF HIV/AIDS EPIDEMIC 
AS OF END 2001
TOTAL NUMBER OF ADULTS AND CHILDREN 
LIVING WITH HIV/AIDS—40 MILLION Source: unaids
and treatment advances have been accompanied by
recent increases in risk behavior. 
As aids advances further into its third decade, the ques-
tion facing the global community is whether we will have
the commitment and resolve to respond effectively. Will
our expressions of concern be turned into concrete action?
Having failed to prevent the first wave of the epidemic, will
we have the courage and vision to prevent the next one?
f we fail to mobilize against aids, we will deserve
the certain condemnation of history. Effective strate-
gies exist to prevent hiv transmission, and both low-
and higher-income countries have the potential to
put these strategies in place.
Were the world to bring to scale available prevention
strategies, a research team led by who/unaids estimates
we could prevent 28 million of the 45 million new 
infections projected by 2010. By slowing the epidemic’s
projected growth over the next eight years by nearly 
two-thirds, hiv prevention could effectively break the
back of the global epidemic and permit the world to
begin contemplating ultimate victory over the disease.
To achieve such results, we must dramatically scale 
up existing prevention efforts. Pilot prevention projects
must rapidly become comprehensive programs that
reach all those at risk, and obstacles to prevention must
be swiftly overcome.
The resources needed annually to bring existing
prevention efforts to scale—estimated at $4.8 billion
annually17—are completely achievable. The annual cost 
of a global effort to reverse the spread of hiv/aids would
preventing hiv
what is at stake
The fight against hiv transmission is a challenge from
which the world cannot shrink. In region after region, 
the hiv/aids threat continues to grow.
Sub-Saharan Africa
For years, observers have expected the epidemic in
Africa to plateau. Yet, each year, the news grows
grimmer, as infection rates exceed levels previously
thought possible. 
t In Botswana, the nation with the world’s highest
infection rate, median hiv prevalence among 
pregnant women in urban areas increased from 38.5
percent in 1997 to 44.9 percent in 2001. Likewise, 
in Zimbabwe, Namibia, and Swaziland—where infec-
tion rates rival those of Botswana—hiv prevalence
continues to increase.9
t After years of relatively slow increases in West Africa,
infection rates appear to be rising sharply in
Cameroon (from 4.7 percent prevalence in urban
populations in 1996 to national prevalence of 11
percent among pregnant women in 2000) and in
several districts in Nigeria, the continent’s most
populous country.10
Emerging Epidemics
hiv infection is rapidly spreading in several of the
world’s most populous countries, mimicking the
epidemic’s early growth in the sub-Saharan region. 
t Conservative projections suggest that over 2 million
people in Russia will be infected by 2010 in the
absence of effective prevention.11
t Escalating rates of sexually transmitted diseases
could foretell a dramatic expansion of hiv infection
in China, where various groups have estimated that
more than 10 million people could be living with
hiv/aids by 201012 from as high as 1 million today.13
t In India, hiv prevalence among women in prenatal
care already exceeds 2 percent in one state and is
more than 1 percent in four others.14
Other Developing Countries
hiv also continues its relentless assault on the
Caribbean, the world’s second most affected region,
where hiv prevalence in at least two countries already
exceeds 4 percent. The number of people infected grew
by nearly 20 percent in North Africa and the Middle 
East last year, leaving close to half a million people 
with hiv/aids.15
Industrialized Countries
In North America and Europe, where hiv prevention
has been most successful, syphilis outbreaks and
behavioral surveys indicate an increase in risk behavior,
especially among men who have sex with men.16
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This report’s call for a dramatic strengthening in hiv
prevention efforts occurs at a key turning point in the
global response to aids. The global community is 
now confronting inequities in access to hiv therapies,
including antiretrovirals (arvs). A major new effort 
to prevent hiv infections should be integrated with 
a comparable expansion in health care access in
resource-poor countries.
Prevention and care are essential partners in an
effective response to aids. hiv prevention supports
efforts to expand health care access by keeping the 
cost of future treatment demands from spiraling ever
upwards. Similarly, availability of treatment helps
promote effective prevention by encouraging early
knowledge of serostatus. By implicitly valuing the 
health and well-being of people living with hiv/aids,
expanded treatment programs also help reduce the
stigma associated with the disease. 
Moreover, access to treatment is a global humanitarian
imperative. Possessing the resources and know-how
needed to intervene, the world must act to reduce
suffering and death among the 40 million people living
with hiv.
The potential impact of improved treatments on 
hiv risk behaviors should be taken into account when
expanding hiv prevention. In industrialized countries,
as improved treatments have become readily available,
the commitment to hiv prevention has failed to keep
pace, and many people at risk of infection have 
abandoned risk reduction strategies.18
prevention and treatment
natural partners in the global ﬁght
against hiv/aids
amount to only about $5 for each person living in the
United States and Europe.
More than money, though, will be required to mount
a comprehensive hiv prevention effort. Although devel-
oping countries possess the passion, intelligence, and
commitment needed to defeat hiv/aids, they often lack
the human and physical capacity to immediately bring
hiv prevention programs to scale. An emergency global
effort to transfer hiv prevention know-how and technolo-
gies must accompany a rapid increase in hiv prevention
spending.
To achieve the needed global mobilization, hiv
prevention proponents will need to squarely address
lingering skepticism regarding what can realistically be
achieved in both developed and developing countries. It
is assumed by many policymakers that little can be done
to reduce the burden of hiv/aids in hard-hit countries,
that tens of millions more will die, and that we have little
choice but to watch until the epidemic reaches its satura-
tion point and begins to die out on its own. 
The prevailing air of inevitability regarding the future
of aids ignores not only the extraordinary resources at
the world’s disposal but also the fact that our knowledge
base on effective prevention strategies has grown
substantially in recent years. Such thinking also defies
experience in sub-Saharan Africa, Southeast Asia, and
Latin America—where some of the poorest countries in
the world have made major progress in stemming the
spread of hiv—as well as the success of industrialized
countries in containing the epidemic.
Global political support for hiv prevention, some-
times lacking in the past, is growing notably stronger.
Caribbean nations have joined together in a major effort
to respond to hiv/aids; African leaders vowed at the
2001 Abuja summit to prioritize the fight against the
epidemic; heads of government of the 10 asean member
countries pledged their leadership in the fight against
hiv/aids in November 2001; and leaders of the
Commonwealth of Independent States in 2002 openly
acknowledged the need to wage a vigorous fight against a
rapidly growing regional health threat. For the first time
in the epidemic’s history, nations joined together in June
2001 at the United Nations Special Session on hiv/aids
to agree on concrete, time-bound targets for reducing the
number of new infections, underscoring the conviction
that the battle against hiv/aids is one that can be won.
And the new Global Fund to Fight aids, Tuberculosis and
Malaria represents an important new avenue for funding
of hiv prevention, although funds pledged thus far are
only a fraction of what will be needed.
Effective hiv prevention is more than education, and
more than a condom, a clean needle, or any other single
commodity. Effective hiv prevention involves a
thoughtful, planned combination of interventions and
policies that work synergistically to reduce overall rates 
of transmission. 
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Every moment of delay in invigorating the global
prevention effort means lives lost. Each day, nearly 14,000
people become infected with hiv, including more than
1,600 infants.19 Without sustained progress in preventing
new infections, millions will die, key national sectors will
collapse, global inequities will grow, and international
development will be undermined for generations.20
Enhanced investment in hiv prevention today will
yield monumental dividends tomorrow for the entire
world—especially for the resource-poor developing 
countries that have been affected the most. By helping
avoid countless infections, current hiv prevention 
strategies are among the most cost-effective health 
interventions available for use in low and middle-income
countries. 
The importance of immediate implementation of a
comprehensive hiv prevention effort is apparent from
earlier history in the epidemic. In 1993, the who Global
Programme on aids projected that an investment of $1.5
billion to $2.9 billion annually could prevent half of all
projected infections in 2000 and save $90 billion in
associated costs. Having failed to intervene effectively, the
world confronts not only an expanding epidemic, but also
escalating costs for both hiv prevention and treatment. 
The Global hiv Prevention Working Group—
composed of leading experts in public health, clinical
care, and biomedical, behavioral, and social research, 
and people affected by hiv/aids, and convened by the
Bill & Melinda Gates Foundation and the Henry J. Kaiser
Family Foundation—seeks to generate a dramatically
expanded commitment to the global fight against hiv
transmission. 
This first report by the Working Group addresses a
pivotal question confronting global decision-makers—
How do we bring available hiv prevention strategies to scale
in order to cripple the global epidemic?
This report summarizes available evidence on the
effectiveness of hiv prevention and identifies logistical
obstacles to immediate scale-up. As this report explains,
rapid implementation of effective prevention programs is
entirely achievable, but only if the world devotes unprece-
dented resources and attention toward this effort.
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ver the past two decades, available prevention
strategies have been repeatedly evaluated in
controlled scientific studies and descriptive
case analyses, and they have been successfully
put to use in multiple populations, in developed and
developing countries, and in both early and mature
epidemics. In short, we know much about what works.
But to have a significant impact on the future course
of the epidemic, proven prevention strategies must be
scaled up and multiple prevention approaches must be
combined to achieve success. Much as combination anti-
retroviral therapy slows viral replication by attacking hiv
from multiple angles, “combination prevention”21 fights
national and local epidemics by adopting multiple strate-
gies to reduce or eliminate the risk of transmission.
Countries that have been most successful in thwarting
hiv/aids have pursued a “combination prevention”
approach. Switzerland, Australia, and other developed
countries that effectively contained emerging epidemics
in the 1980s combined sound prevention strategies,
targeted interventions, sustained efforts to reduce stigma,
and broad general awareness campaigns. 
Likewise, developing countries that have recorded
major prevention successes have promoted condom use,
raised general awareness of the aids threat, provided sex
education in schools, targeted prevention interventions to
populations at special risk, expanded access to voluntary
counseling and testing, involved multiple sectors
(including ngos and faith communities) in the fight
against aids, and enacted strong human rights protec-
tions for people with hiv/aids.22
Available hiv prevention strategies are extraordinarily
cost-effective. Basic hiv prevention interventions cost
substantially less per disability-adjusted life year (daly)
saved than the accepted $50 per daly cost-effectiveness
threshold for health interventions in resource-poor
settings—$1 per daly for condom distribution to women
with multiple partners in sub-Saharan Africa, $5 for
implementation of basic blood safety practices, $4 to 7
for peer education targeting sex workers, $5 to 12 for
nevirapine to prevent mtct, and $12 for std control.
Indeed, existing tools to reduce hiv transmission appear
to be among the more cost-effective standard interven-
tions currently available for health conditions that prima-
rily affect resource-poor countries.23




The most frequent mode of hiv infection, sexual trans-
mission, is normally a result of unprotected vaginal or
anal intercourse. Worldwide, heterosexual transmission
is responsible for the majority of new hiv infections.
Estimates of the probability of hiv transmission per act
of heterosexual intercourse have varied between different
countries and settings. A recent study of a representative
sample of heterosexual couples in Uganda found the
probability of transmission per act to be 0.1 percent.24
Commercial sex workers represent an especially
vulnerable and epidemiologically important population
for the sexual transmission of hiv. Because their very job
definition mandates exposure to multiple sexual encoun-
ters, sex workers are often the first discrete population in
emerging epidemics to exhibit noteworthy hiv preva-
lence. unaids, citing recent experience in Asia, advises,
“[I]t is from the comparatively small pool of sex workers
first infected by their clients that hiv steadily enters the
larger pool of still-uninfected clients who eventually
transmit the virus to their wives and partners.”25
Men who have sex with men (msm) make up 5 to 10
percent of hiv infections globally and up to 70 percent 
of infections in industrialized countries.26 Official 
surveillance figures may, however, understate the extent
of transmission via sexual contact between men, as such
contact may not always be acknowledged by individuals
who test positive or by national authorities. Most cases 
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PROVEN HIV PREVENTION STRATEGIES
9unaids and others have extensively documented the
success of countries and individual programs in
promoting safer behaviors and reducing hiv infections.27
t Brazil has combined targeted prevention efforts,
general awareness campaigns, universal access to
antiretrovirals (arvs) and other hiv treatments, and
supportive policies to enhance the effectiveness of
prevention and care initiatives. In addition to marked
reductions in hiv-related morbidity and mortality,
Brazil has witnessed significant declines in risk
behavior, reductions in new infections, and increased
demand for voluntary counseling and testing (vct).
National surveys, for example, indicate that condom
use among injection drug users increased from 42
percent to 65 percent from 1999 to 2000.28
t Cambodia embarked in the 1990s on a comprehensive
national hiv prevention program. As a result, between
1997 and 2000, hiv prevalence among pregnant
women declined by almost one-third, and Cambodian
males reported an increase in condom use.29
t Senegal avoided the fate of many of its neighbors by
implementing a multisectoral hiv prevention effort as
its epidemic was only beginning to emerge. Although
neighboring countries now have hiv prevalence in
excess of 5 percent, Senegal has managed to keep its
level of infection under 2 percent. A key element to
Senegal’s success has been the active involvement of
civil society.30
t Thailand has perhaps the best-studied epidemic in 
a developing country. After experiencing escalating
infection rates in the 1980s, Thailand initiated a
comprehensive prevention program that included its
100 percent condom program targeting brothels,
broad-based awareness efforts, the active involve-
ment of multiple sectors of society, and strong
human rights protections. By the end of the 1990s,
the number of new infections had fallen by 80 percent
from levels reported prior to Thailand’s implementa-
tion of its national prevention program.31
t Uganda, with strong and vocal support from Presi-
dent Yoweri Museveni, implemented a multi-compo-
nent hiv prevention program that includes broad
public awareness efforts, extensive condom promo-
tion, and access to free voluntary counseling and
testing. ngos and organizations of people living with
hiv/aids have played an especially visible role in
Uganda’s national hiv prevention effort. Thanks to
such multi-sectoral efforts to prevent transmission,
hiv prevalence among pregnant women in urban
areas in Uganda declined by nearly two-thirds
between the beginning and end of the 1990s, and
national hiv prevalence was cut nearly in half.32
t Zambia has in recent years initiated a multi-discipli-
nary national aids program in an effort to reduce the
number of new infections. The program appears to
be bearing fruit, as hiv prevalence among pregnant
urban women (ages 15 to 19) fell by nearly 50 percent
between 1993 and 1998.33
t Industrialized countries have recorded important
successes in containing their own hiv/aids
epidemics. In the U.S., for example, a combination 
of hiv prevention strategies helped reduce the annual
number of new infections from 150,000 in the 
mid-1980s to 40,000 by the early 1990s.34 And by
aggressively responding with prevention programs
targeting men who have sex with men and injection
drug users, Australia contained a potentially serious
hiv/aids epidemic at a low level. 
t Individual projects have shown success within 
countries. Workers in Zimbabwe factories where 
peer hiv/aids education programs were imple-
mented had a 34 percent lower rate of new infections
than individuals employed in factories that had no
peer interventions.35 In Côte d’Ivoire, peer education,
combined with voluntary counseling and testing, 
has helped reduce hiv prevalence among sex workers
in Abidjan from 89 percent in 1992 to 32 percent in
1998. Community-based prevention services focusing
on sex workers in Benin have similarly contributed 
to an increase in condom use in this population from
6 percent in 1993 to more than 80 percent six years
later, as well as a significant decline in incidence of
sexually transmitted diseases.36 
hiv prevention
real-world proof of success
of hiv transmission among msm stem from unprotected
anal intercourse, although there appears to be a real, but
much smaller, risk of transmission from oral sex.37
An important subset of sexually transmitted cases of
hiv involves sexual activity that occurs when one or both
participants are under the influence of various
substances, such as drugs or alcohol. Intoxicants may
increase risk for transmission by clouding individual
judgment and reducing inhibitions regarding behaviors
that facilitate hiv transmission.38
Effective interventions to prevent sexual transmission
include behavior change programs, prevention and treat-
ment of sexually transmitted diseases (stds), and volun-
tary counseling and testing (vct). Interventions with
theoretically strong, but unproven, potential to reduce
sexual transmission of hiv include male circumcision
and clinically appropriate antiretroviral (arv) treatment of
sexually active, hiv-infected individuals.
Behavior Change Programs
Programs to encourage safer sexual behaviors are
anchored in a wide range of recognized behavioral theo-
ries. Theory-based prevention programs include those
that attempt to directly alter personal beliefs, attitudes
and behaviors, as well as interventions that indirectly
seek to influence personal behavior by affecting social
networks and community norms.39 Specific behavioral
approaches include social marketing, small group inter-
ventions, safer sex workshops that provide information
and build skills, and popular opinion leader and peer-
based interventions, including those that seek to model
positive attitudes toward safer sex.40 These approaches
seek to increase condom use among people who are 
sexually active, persuade individuals to reduce their
number of sexual partners, and encourage young people
to remain abstinent or delay initiation of sexual activity. 
Safer sex programs have proven effective in a broad
range of populations, including school-age youth,41
heterosexual women,42 and men who have sex with
men.43 Effective safer sex programs should be carefully
tailored to the particular social and economic settings in
which they are implemented and to the specific needs
and values of the target population. In addition, safer 
sex initiatives are optimally effective when they are
undertaken in combination with broad-based sexuality
and hiv/aids education. Because vulnerability to hiv is
often greatest in groups that are socially marginalized or
legally powerless—e.g., women who lack economic
power, youth who are dependent on their elders, sex
workers at risk of arrest, or men who have sex with men
at risk of ostracism or harassment—it is important to
involve members of the target population in the design
and implementation of behavior change initiatives in
order to ensure the cultural relevance of such programs. 
In areas where the virus is present, populations at
greatest risk of sexual transmission will be those who
have multiple sexual partners, such as sex workers. 
Thailand’s success in promoting condoms in brothels 
has been rightly hailed as a sentinel prevention success,
but the country is not alone in generating safer sexual
behaviors among sex workers. In Abidjan, targeted
prevention efforts helped raise condom use among sex
workers from 20 percent in 1992 to nearly 80 percent 
six years later, slashing hiv prevalence in this population
by nearly two-thirds. unaids has also documented the
success of hiv prevention programs targeting sex
workers in Papua New Guinea, India, and Bangladesh.44
Although the impact of safer sex programs has often
been measured by increased rates of condom use, growing
information regarding successful national prevention
efforts underscores the many factors that may combine to
reduce the rate of sexual transmission. In Uganda, for
example, critical factors in the country’s success in slowing
the spread of hiv include a marked reduction in the
median number of sexual partners and a delay by two years
in young people’s initiation of sexual activity. Likewise, in
Thailand, while the increase in use of condoms strongly
contributed to the decline in new infections, a similarly
important development was a reduction in the frequency
with which Thai males patronize brothels. 
While safer sex programs can have an enormous
impact on national epidemics, as demonstrated by 
extensive scientific evidence and real-world experience,
even the most effective efforts fall short of achieving 100
percent use of condoms by the target population. When
healthy sexual behavior norms are forged, such behaviors
are often difficult to sustain over time. To maximize their
effectiveness, safer sex messages must be repeated and
revised, as well as supplemented by additional prevention
interventions. Although safer sex programs often
encourage young people to remain abstinent, research
indicates that comprehensive programs are more 




Sexually transmitted diseases increase hiv risk by at least
two to five times.46 Untreated stds enhance the infectivity of
hiv-positive individuals and render uninfected people more
susceptible to transmission of the virus.47 Experts agree that
an integral component of a comprehensive hiv preven-
tion effort is the early detection and treatment of stds.48
In a study in the Mwanza region of Tanzania, 
continuous provision of std drugs by trained health care
providers reduced hiv incidence in six intervention sites
by 38 percent.49 By contrast, a study of periodic mass std
treatment in the Rakai district of Uganda found that the
intervention significantly reduced the number of stds
but did not reduce hiv incidence.50
While the totality of available evidence strongly
supports the importance of early detection and treatment
of stds as an essential hiv prevention mechanism—in
both mature and early epidemics51—the questions raised
by the Rakai and Mwanza results underscore the need 
for additional research to identify optimal intervention
strategies, especially in established epidemics.52 To 
maximize epidemiologic impact and cost-effectiveness,
enhanced std control efforts should be initiated as early
as possible in the course of an epidemic and be targeted
toward people at highest risk of acquiring and transmit-
ting hiv and other stds.53 std screening episodes should
be ideally coupled with client-centered risk reduction
counseling, which has been shown to reduce behaviors
that may result in transmission of hiv or other stds.54
Viral stds that are not curable, especially herpes
simplex virus (hsv-2), facilitate hiv transmission.
Research evaluating the effectiveness of hsv-2 treatment
in reducing hiv transmission is urgently needed. At
present, treatments for hsv-2 are largely unavailable in
low-income countries due to their relatively high cost. 
Voluntary Counseling and Testing
The vast majority of people living with hiv/aids in low-
income countries are unaware they are infected, a factor
that substantially weakens efforts to respond effectively 
to hiv/aids in resource-limited settings. Voluntary 
counseling and testing (vct) is not only a gateway to care
for people living with hiv but also a critical component 
of a comprehensive strategy to prevent hiv transmission.
Studies have documented that people who test positive
tend to reduce behaviors that can transmit hiv.55 Data are
less conclusive regarding the impact of a negative test
result on risk behavior. 
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Characteristics of Successful National Prevention Programs
unaids and others have studied countries where hiv prevention efforts have been most successful in order to identify
common characteristics.56 These include:
t Strong leadership, including visible ownership by national leaders of the fight against the disease.
t Broad awareness of hiv/aids among the general population.
t Open discussion of sex and a national commitment to sex education for youth.
t Active involvement of multiple sectors of society (including civil society, religious leaders, and non-governmental
organizations) in the response to aids.
t Concerted efforts to reduce aids stigma, and policy and legal changes to prevent hiv-related discrimination.
t Availability of external assistance in the financing, development, and implementation of effective prevention programs. 
South Africa’s loveLife Program:
Empowering Youth to Protect Themselves from hiv
South Africa’s national hiv prevention program for
youth, known as loveLife, seeks to empower young
people in South Africa to protect themselves through a
multi-component program that includes saturation of
youth-oriented media with hiv awareness messages;
expansion of adolescent health services in South
Africa’s 5,000 public health clinics; creation of a
national network of youth centers that provide health
services in a non-clinical setting; and mobilization 
of a national corps of youth peer outreach volunteers.
loveLife has been widely embraced by youth in South
Africa, and nearly 70 percent of young people who
have heard of loveLife say they have reduced their
number of sexual partners as a result of the program.
loveLife is a partnership between U.S.-based private
foundations, leading South African non-governmental
organizations, the South African government, and
South Africa’s largest media corporations.
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Young people will determine the future of the hiv/aids
epidemic. In sub-Saharan Africa—where more than one-
half the population is under age 18—the decisions made
over the next several years by young people will dictate
whether, as projected, three out of four of today’s 15-year-
olds in Lesotho will be hiv-infected by age 50.57
Currently, we are losing the fight to protect the health
and well-being of the world’s youth. Nearly 12 million
people between ages 15 to 24 are living with hiv/aids,
and young people account for half of all new infections—
2.5 million each year, more than 7,000 every day.58
To reach youth with effective hiv prevention strate-
gies, it is critical to intervene at an early age, before
young people become sexually active. 
Why Youth Are Vulnerable to hiv
t Early Initiation of Sexual Activity. Substantial percent-
ages of young people become sexually active before their
15th birthday—nearly 1 in 2 boys in Gabon; roughly 1 in 
3 boys in Kenya, Malawi, Latvia and Poland; more than 
1 in 4 girls in Niger.59 In some Eastern European 
countries, still struggling to find social equilibrium in 
the transition to a market economy, there is evidence 
that young people are, on average, initiating sexual
activity at an increasingly early age.60
t Ignorance of the Dangers of hiv. Surveys in Central
Asia, where hiv infection is on the rise, indicate that 10
percent or fewer of adolescents between ages 15 to 19 have
ever heard of aids, and only 9 percent of adolescent girls in
Ukraine are aware of how to prevent hiv transmission.61
Likewise, unicef reports that, in Mozambique, 74 percent
of young women and 62 percent of young men, ages 15 to
19, do not know how to protect themselves from hiv.62
t Sexually Transmitted Diseases. In both rich and poor
countries, stds disproportionately affect people between
ages 15 to 29, increasing their susceptibility to hiv trans-
mission. Countries in Asia and Eastern Europe, where
hiv/aids is emerging as a serious threat, have recently
experienced disturbing increases in stds. In addition,
studies in the U.S. indicate that African-American 
adolescent girls are at especially high risk for chlamydia
and other stds.63
t Young Women. Not only are adolescent girls more 
physiologically vulnerable than
mature women to hiv infection
and other sexually transmitted
diseases, but many young girls
have sex with older men, who are
more likely than young men to be
infected with hiv. Condom use is
rare among adolescent females,
according to studies in sub-
Saharan Africa.64 As a result of
such factors, young women tend
to have higher hiv infection rates
than young males.65 In five sub-
Saharan African countries (e.g.,
Botswana, Lesotho, Namibia,
South Africa, Zimbabwe) where
at least 1 in 5 females between 15
to 24 are hiv-infected, infection
rates for young females are more
than twice as high as for males. 
hiv prevention for youth
a global imperative 
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t Powerlessness. In virtually all cultures, youth lack
social and political power, making them vulnerable to
sexual exploitation. Many young people (especially girls)
are coerced, either physically or economically, into
becoming sex workers; unicef reports that half of all sex
workers in India are under age 18 and 20 percent are
under age 15.66 Although universal education initiatives
help reduce young people’s vulnerability, aids is under-
mining such strategies by devastating educational
sectors, especially in sub-Saharan Africa. 
t Orphans. Studies in both rich and poor countries
demonstrate that children who are able to discuss
hiv/aids and other problems with their parents are less
likely to become infected. Conventional family supports,
however, do not exist for the more than 14 million 
children who have been orphaned as a result of aids,67
underscoring the need for targeted programs to assist
and educate such young people. 
t Resistance to Speaking Frankly to Young People.
In most countries, there is strong resistance to speaking
frankly to youth about sensitive topics such as sexuality
and drugs. Although such resistance derives from
powerful cultural traditions, it can have deadly 
consequences. 
Effective Prevention Strategies for Youth
Extensive research has demonstrated that hiv prevention
programs can successfully encourage young people to
remain abstinent, delay initiation of sexual activity, or, if
sexually active, use a condom.
t Peer Programs. International experience—in developed
and developing countries—demonstrates that peer-based
interventions can be powerfully effective in promoting
safer sexual behaviors and reducing drug use among
young people.68 The M-Powerment project, for example—
which uses a variety of peer-based, youth-oriented strate-
gies to instill safer sex norms among young men who
have sex with men in the United States—has been found
to reduce reported risk behaviors.69
t Social Marketing. Just as makers of consumer products
use marketing techniques to entice young people to buy
their wares, evidence reveals the effectiveness of “social
marketing” in promoting condom use, health service
utilization, and other healthy behaviors among young
people.70 Efforts to market responsible sexual behaviors
frequently focus on key elements of youth culture,
including music and sports.
t School-Based Sex Education. Inadequate education
about human sexuality and hiv/aids is having deadly
consequences. unaids reports that more than half of all
young people in Kenya say they do not believe condoms
protect against hiv; nearly two out of three sexually active
teenage girls (15 to 19) in Haiti say they are not at risk of
hiv infection.71 Studies indicate that school-based
hiv/aids programs not only provide young people with
potentially life-saving information, but reinforce healthy
norms by providing youth with a supportive environment
that involves parents and other community members.72
Research further indicates that comprehensive sex educa-
tion is more effective in reducing hiv risk than programs
that promote abstinence as the sole means to avoid hiv
and other stds.73
t Youth-Friendly Services. Conveniently located, youth-
friendly health services that involve young people as peer
counselors have been found to increase clinic attendance.
Youth-oriented behavior change programs have proven to
be especially effective when integrated with other youth
services. According to unaids, research in Zimbabwe
indicates that membership in a community youth group
significantly reduces the chance that young women will
become infected with hiv.74
t Real-World Proof. Even in resource-poor countries,
prevention programs that target youth can be powerfully
effective. In Uganda, young people’s delay in initiating
sexual activity has been a critical factor in that country’s
success in slashing rates of new infections. Strong hiv
prevention efforts have also sharply reduced hiv preva-
lence among young pregnant women in Zambia.75
To have maximum impact on the epidemic, programs 
to reduce sexual transmission must be dramatically
expanded. At present, fewer than 1 in 5 people at risk 
of infection worldwide have access to basic prevention
interventions.76
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In a randomized trial involving more than 3,100 
individuals and nearly 600 couples in Kenya, Tanzania
and Trinidad, participants who received vct were signifi-
cantly more likely to reduce reported risk behaviors than
participants who received basic health information.
Declines in risk behaviors were notably pronounced for
trial participants who tested hiv-positive and for couples
who learned that one partner was infected.77
Knowledge of serostatus alone, however, is often not
sufficient to produce long-lasting behavior change. vct
appears to be most effective and longer-lasting as an hiv
prevention tool when testing is combined with intensive
counseling and other prevention services.78
The ultimate effectiveness of vct as an hiv prevention
strategy depends, of course, on the willingness of people at
risk to voluntarily seek this intervention. Social marketing,
an approach that uses state-of-the-art product marketing
techniques to promote healthy behaviors, has proven effec-
tive in encouraging people to take various risk reduction
steps, including being voluntarily tested for hiv.79
Circumcision
Several studies have found that uncircumcised men have
notably higher hiv infection rates than their circumcised
counterparts.80 Some health experts believe circumcision
should become routine for newborn males in high-
prevalence settings and should be actively promoted for 
adolescents and adults.81
While the bulk of evidence points toward a role for
circumcision in reducing male hiv risk, at least one
study has called this finding into question.82 In particular,
some have suggested that circumcision may function 
as a proxy for cultural differences that affect sexual 
practices and hiv risk.83 Others note that studies linking
circumcision with a reduced risk of hiv transmission
have focused only on men who were circumcised at 
birth, and that no studies have linked adult circumcision
with a reduction in hiv transmission. Experts convened
by unaids and who advised in 2000: “[T]he association
between male circumcision and hiv/std transmission
remains unclear and further research in this area is
necessary before clear recommendations can be made.”84
Antiretroviral Therapy
Studies have consistently found that risk of hiv transmis-
sion is directly associated with the infected individual’s
viral load in plasma.85 Recognized combinations of 
available arvs reduce viral load in most patients, often 
to undetectable levels.86 Although the proposition remains
unproven, some experts have speculated that widespread
use of arvs in accordance with accepted treatment guide-
lines could have important positive effects on population-
wide rates of hiv transmission.
Consensus regarding the advisability of viewing arvs
as a primary prevention tool is lacking for several reasons.
While it is plausible that arv-induced reductions in viral
load may decrease the likelihood that individuals with hiv
might transmit the virus sexually, no study has demon-
strated this to be the case. Researchers report that hiv-
infected men with undetected viral rna in plasma may still
harbor the virus in seminal cells and be capable of trans-
mitting hiv to a sexual partner, especially one who has
inflamed mucosa.87 Moreover, arv therapy is typically initi-
ated many years after initial infection, potentially limiting
any public health impact it might theoretically have. 
Caution is further merited by the possibility that 
any prevention benefit from arvs might be offset by 
an overall increase in risk behavior stemming from 
optimism over therapeutic advances. Indeed, there is
some evidence that this may already be the case in 
North America and Europe.88
Other Barrier Methods
Although the bulk of attention has been directed toward
the male condom as the key prevention tool for sexually
active people, the female condom has been proven 
effective in reducing the risk of transmission.89 Surveys
also indicate the product would be used by many sexually
active women were it more widely accessible.90 Substan-
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Integrating std Control and hiv Prevention in India
India targets rural populations for enhanced std
prevention and treatment services during 15- to 20-day
“pulse campaigns” every six months. Health care
workers and local government representatives make
house-to-house visits to increase awareness of std
services, and health camps offer local residents free
std screening and treatment. Started as a pilot project
in April 1999, the effort now covers all administrative
districts in India. Out of a target population of 326
million people in 2001, 71 million (22 percent) attended
the health camps, with 3 million (4.2 percent) actually
receiving std treatments. Sentinel surveillance in 2001
detected declines in hiv prevalence among std clinic
attendees in some high-prevalence states of India.
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tially greater efforts are needed to increase access to 
this potentially important prevention tool.
Some experts have also theorized that the female
diaphragm may reduce risk of hiv transmission during
vaginal intercourse because it covers the cervix, an 
important target for hiv infection. Studies are presently
being developed to assess the effectiveness of the female






Direct exposure to the virus through the bloodstream 
is the most efficient route of hiv transmission. Most
cases of parenteral transmission occur as a result of the
sharing of needles during injection drug use, but a
notable percentage also stem from improper blood 
collection and transfusion practices.
Injection drug use accounts for an estimated 10
percent of the world’s hiv infections, although it is the
cause of a majority of infections in certain Asian and
European countries.94 The potential for an increase in
drug-related hiv transmission is considerable. Whereas
only 80 countries reported to the United Nations in 1992
that injection drug use had been documented within
their borders, by 1998 the number had grown to 136.95
Although injection drug use is distinct from sexual
intercourse as a mode of transmission, the two routes are
frequently linked epidemiologically. Injection drug users
are often young and sexually active, potentially exposing
their sexual partners to the virus. In addition, injection
drug users disproportionately work in the commercial
sex industry. 
The transfusion of hiv-infected blood or blood prod-
ucts is believed to be responsible for 5 to 10 percent of
cumulative infections worldwide.96 Substandard hygienic
practices in health care settings—including improper ster-
ilization and the reuse of medical equipment—also pose a
risk of hiv transmission, although the precise contribu-
tion of such practices to the spread of hiv/aids is unclear. 
hiv Prevention Among Injection Drug Users
More than 20 years’ experience in responding to aids has
helped identify a variety of cost-effective interventions
that significantly reduce the risk of hiv transmission
through needle sharing:
Needle and Syringe Projects
Needle exchange projects have been shown to reduce the
risk of transmission without contributing to an increase
in drug use.97 Indeed, extensive research points to early
implementation of needle and syringe projects as a 
critical factor in helping several cities avoid a serious 
hiv outbreak among idus.98 An international analysis 
of available data found that hiv prevalence decreased 
5.8 percent in 29 cities with needle and syringe projects,
while hiv infection increased nearly 6 percent in 51 cities
without such programs.99
Evidence of the effectiveness of needle and syringe
projects is well illustrated by experience in New York City,
which is perhaps home to more idus than any other
municipality in the world. Following tens of thousands 
of hiv infections among New York idus in the 1980s,
several needle and syringe projects were initiated in
neighborhoods frequented by idus. Between 1991 and
1996, hiv incidence among the city’s idus declined by
more than 40 percent.100 More recently, public health 
officials determined that hiv prevalence among first-
time testers at drug treatment centers dropped from 
33.6 percent in 1990 to 4.3 percent in 1998.101
In addition to providing clean injection equipment,
needle and syringe projects link users with other
Promoting Voluntary Counseling and Testing In Uganda
Access to, and promotion of, voluntary counseling
and testing (vct) has been a key component of
Uganda’s successful effort to reverse a potentially
catastrophic hiv/aids epidemic. Uganda has made
vct available since 1990 and has closely coordinated
its testing program with counseling services provided
by The aids Service Organization (taso), a commu-
nity-based, non-governmental organization.
In Kampala alone, more than 380,000 people had
been tested by 1999.91 Studies in Uganda have docu-
mented marked positive changes in sexual behavior
following vct, with reported condom use among
testers increasing from 10 percent to 89 percent with
steady partners and from 28 percent to 100 percent for
non-steady partners.92 Uganda also offers vct free of
charge in various rural settings, and evaluations have
similarly documented positive behavior changes
among rural residents following vct.93
programs that promote risk reduction. As the National
Institute on Drug Abuse concluded following a compre-
hensive survey of available evidence, needle exchange
and syringe projects “serve as a bridge to active and 
out-of-treatment drug users by providing them with
hiv/aids information and materials (e.g., bleach kits and
condoms) to reduce their risks, by offering opportunities
for hiv testing and counseling, and by providing referrals
for drug abuse treatment and other social services.” 102
Needle and syringe projects are often hampered by 
law enforcement agencies and the communities in which
such programs are situated. Numerous programs in 
both developed and developing countries have managed to
overcome such obstacles to reach idus at risk of infection,
underscoring the importance of enhanced technical assis-
tance to fledgling programs. Policy and legal obstacles to
needle and syringe projects have also been successfully
overcome in both developed and developing countries. 
Drug Treatment
Methadone maintenance and other forms of substance
abuse treatment are effective in preventing hiv transmis-
sion.103 Not only does drug treatment reduce drug use
and therefore help prevent practices that can lead to hiv
transmission,104 but initiation of drug treatment often
produces significant reductions in hiv-related sexual risk
behaviors.105
Behavior Change Programs
Small group interventions, individual counseling, and
other psychosocial programs have also proven effective 
in encouraging many idus to reduce the frequency 
with which they inject drugs or have unprotected sex.106
Community-based outreach has been shown to be 
especially effective in encouraging idus to access 
available prevention options.107
Psychosocial interventions for idus appear most 
effective when they are intensive and long-lasting,108
but not all people are willing to make such an extended
personal investment. Moreover, behavior change
programs for idus seem to have been more successful in
encouraging safer injection practices than safer sex.109
Improving the Safety of the Blood Supply
Development in the 1980s of a test to detect antibodies to
hiv enabled developed nations to routinely screen blood
donations for antibodies to the virus, and donor restric-
tions further reduced the likelihood of transfusion-related
hiv transmission. By the end of the epidemic’s first
decade, the risk that hiv would be transmitted through
donated blood had been virtually eliminated in developed
countries.110
To extend these benefits to developing countries,
public health experts recommend implementation of a
range of policies and procedures, including creation of a
national blood service, use of low-risk donors, routine
screening of blood donations, and reduction of unneces-
sary transfusions.111 Significant financial and technical
support is needed to permit developing countries to
implement such policies and practices to protect blood
supplies. 
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Overcoming Potential Obstacles to Needle and
Syringe Projects in India
In recent years, hiv infection among idus in the
Manipur state of India skyrocketed, striking an esti-
mated 60 percent of users. Evidence suggested that
needle sharing was abetted in part by the fears of
idus that they would be arrested if found with needles
and syringes. 
When the Society for hiv/aids and Lifelines 
Operation established a needle and syringe project in
Churachandpur township, the group consulted local
police and persuaded them not to harass participants
or staff who might possess injection equipment.
Between 1997 and 2001, hiv incidence among idus
in Manipur dropped from 77 percent to 59 percent.
Although the rate of infection remains high, the
success of the program in reaching a highly vulnerable
population with important health promotion services
convinced the minister of health to integrate needle
exchange into the State’s official hiv/aids strategy. 
Prevention of hiv Transmission Among Injection
Drug Users in Eastern Europe
The Open Society Institute has played an important
role in expanding prevention services for injection
drug users, with particular emphasis on emerging
epidemics in Eastern Europe and Central Asia. 
osi’s International Harm Reduction Development
Program and associated foundation partners provide
funding and other support to 162 harm reduction 
projects in 22 countries. These projects—which seek
to reduce drug-related harm and promote human
rights—serve more than 50,000 clients each month.
osi projects support harm reduction efforts for 
prisoners, sex workers, and homeless youth.
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Improving the Safety of Health Care Settings
Industrialized and many middle-income countries have
long required workers to take “universal precautions” in
health care settings to prevent transmission of hiv and
other bloodborne pathogens. This approach, which treats
each patient as potentially infectious, requires that
workers routinely wear gloves, masks, goggles, and other
protective gear, as well as properly sterilize equipment,
devices, and surfaces. Health care institutions should be
designed to promote safety (such as having repositories
for the disposal of needles and other sharp devices), and
workers should have access to the safest possible syringes
and other devices. Although universal precautions cannot
prevent all possible exposures to blood, this approach has
succeeded in making transmission extraordinarily rare 
in health care settings in industrialized countries.112
To achieve similar success in resource-limited 
countries, health care facilities require access to safer
technologies, workplace training in infection control, 
and assistance in developing and implementing policies






Each year, an estimated 2.5 million hiv-infected pregnant
women give birth. As a direct result, nearly 800,000
newborns contract hiv each year from their mothers,
accounting for 16 percent of all new infections.
hiv transmission from mother to child may occur
during pregnancy, labor, or delivery, or as a result of
breastfeeding. Children exposed to hiv—either before 
or during delivery, or through breastfeeding—currently
stand a roughly 3-in-10 chance of becoming infected,
with the risk of transmission greater for infants who 
are breastfed.113
While the best strategy for prevention of mother-to-
child transmission (pmtct) is prevention of hiv infection
in women, important advances also make it possible to
prevent most cases of hiv transmission to newborns
when the mother is already infected. After researchers
reported in 1994 that a three-part regimen of azt reduced
the risk of vertical transmission by two-thirds,114 devel-
oped countries adopted a pmtct package consisting of
vct, reproductive counseling and planning, antiretroviral
therapy, and use of elective caesarean delivery. This
approach has rendered vertical transmission a rare event
in the industrialized world.115
Hopes for preventing mother-to-child transmission 
in resource-poor countries gained momentum with the
release of research findings demonstrating the efficacy 
of a short regimen of azt in reducing the likelihood of
infection.116 Momentum accelerated in September 1999,
when researchers from hivnet 012 reported that 
separate single doses of oral nevirapine to mother (at
onset of labor) and to newborn (within 72 hours of birth)
lowered the probability of hiv transmission (at 14 to 16
weeks) by almost 50 percent.117
hivnet 012 gave rise to hopes that, for less than $5
per birth, the risk of transmission could be cut in half—
hopes that were further strengthened when Boehringer
Ingelheim, the maker of nevirapine, indicated it would
provide the drug free for pmtct in developing countries.
In South Africa alone, an estimated 110,000 hiv
infections in infants could be prevented by 2005 were 
the hivnet 012 intervention used for all deliveries.118
Efforts to scale up pmtct projects have revealed,
however, that drug price is only one factor in ensuring
the access of pregnant women to effective prevention
Expanding Efforts to Protect Blood Safety
Today, simple procedures and technology exist that
can effectively eradicate the risk of transfusing 
potentially tainted blood. 
In recent years, many countries have acted to
protect the safety of blood supplies. Countries in sub-
Saharan Africa have integrated blood safety measures
into national aids strategies, and unaids reports that
Cambodia has similarly initiated efforts to prevent hiv
transmission as a result of blood transfusions.
To improve the safety of the blood supply, India has
encouraged voluntary blood donations. This approach
has reduced the number of transfusion-related 
infections from 8 percent of total infections in 1992 
to 3 percent of total infections in 2001. During this
period, the proportion of all blood donations that are
voluntary increased from 30 percent to 46 percent.
interventions. Challenges to rapid scale-up of pmtct
include lack of access to voluntary counseling and
testing, inadequate human capacity, obstacles to
caesarean delivery, and the risk of transmission via
breastfeeding.
Voluntary Counseling and Testing. Insufficient access to
voluntary counseling and testing leaves many pregnant
women unaware of their hiv status at the time of
delivery, although pmtct programs may provide a
starting point to spur expanded counseling and testing
services. Some strategies not dependent on hiv testing
have been considered, such as universal treatment with
nevirapine in high-prevalence settings. As experience in
expanding prevention of mother-to-child transmission
programs develops, such strategies should be further
explored.
Capacity. In many parts of sub-Saharan Africa, where
most cases of mother-to-child transmission occur, the
human capacity required to expand and sustain pmtct
projects is presently inadequate. Lack of coordinated
record-keeping between antenatal and maternity settings,
as well as the fact that many women in some countries
give birth at home, have complicated efforts to ensure
timely delivery of arvs to women and their newborns. 
In addition, effective scale-up of pmtct will require
substantial efforts to ensure access to treatment for 
hiv-infected mothers.
Caesarean Delivery. Caesarean delivery prior to labor and
membrane rupture, and in the absence of arvs, also
reduces the risk of vertical transmission.119 Although 
this finding has influenced practice in richer countries,
where it has contributed to the declines in rates of
vertical transmission, applicability in poor countries
remains unclear, given the enhanced possibility in
resource-poor settings of post-operative complications,120
and lack of access to hospital birthing facilities.
Breastfeeding. Although studies have demonstrated 
the public health utility of pmtct even in settings where
breastfeeding is the norm, its public health potential is
nevertheless diminished by the contribution of breast-
feeding to transmission. The postnatal risk of transmis-
sion to the child increases the longer breastfeeding is
continued.121 Ideally, hiv-infected mothers should have
access to alternatives to breastfeeding and receive 
counseling on infant feeding during prenatal care.122
In resource-poor situations where substitutes for breast-
feeding are either not available or inadvisable (due to 
lack of clean water), early cessation of breastfeeding or
heat-treating of breast milk may help minimize postnatal
risk of transmission. Cultural practices and the stigma
associated with failure to breastfeed, however, may deter
some women from using alternatives to breastfeeding.124
In light of evidence indicating a higher risk of transmis-
sion from mixed feeding (breastmilk and formula or
other substance) than exclusive breastfeeding,125 mothers
should be counseled on the superiority of early weaning
over mixed feeding.126
Although every effort should be made to help mothers
protect their newborns from transmission through
breastfeeding, the alternatives to breastfeeding are likely
to remain unfeasible for some time in many low-income
countries. Accelerated research into strategies to reduce
the risk of transmission from breastfeeding is an urgent
global health necessity.
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Scaling Up Efforts to Prevent Mother-to-Child 
Transmission 
The high prevalence of hiv among childbearing
women prompted Thailand to initiate in 2000 a
nationwide program to promote prevention of
mother-to-child transmission. Components of the
program include promotion of routine vct in prenatal
settings; azt for pregnant women beginning at 34
weeks’ gestation, with more intensive azt during
labor; a short azt regimen for newborns; use of
formula instead of breastfeeding; and proper health
care for mothers and children.
Hospital records demonstrate rapid success in
implementation of Thailand’s national prevention
strategy. Among more than 570,000 women who 
gave birth in Thailand from October 2000 through
September 2001, 97 percent received antenatal care—
of whom 93 percent were tested for hiv. Of the more
than 6,600 hiv-positive women giving birth, 69
percent received azt prior to delivery. Nearly 90
percent of infants born to hiv-infected women
received azt prophylaxis, and 83 percent received
infant formula.123
Although Thailand’s success is not automatically
transferable to other settings, especially in least devel-
oped countries with more limited access to antenatal
care and formula feeding, it underscores the possibility
of rapid scale-up of pmtct, especially when such 
initiatives receive strong support from political leaders. 
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o take effective hiv prevention interventions
to scale, countries must overcome a range 
of logistical challenges. Money must be found 
to support the intervention itself, sufficient 
physical infrastructure and human capacity must exist,
and social, legal, cultural, or political factors that would
inhibit success must be addressed. These challenges,
although real, can usually be overcome, even in the
poorest countries of the world. 
Consider the case of Cambodia, a country where per
capita income is among the world’s lowest. Soon after
emerging from a brutal civil war that claimed hundreds
of thousands of lives, the country faced spiraling rates of
hiv infection. Despite lacking the resources available in
wealthier countries, Cambodia nevertheless mobilized to
fight the growth of hiv/aids, using an array of standard
prevention strategies to promote safer behaviors. Today,
as hiv infection rates continue to decline, Cambodia
appears poised to contain what threatened to be a 
devastating epidemic. 
Key impediments to rapid scale-up include:
t A lack of resources for effective hiv prevention programs
t Systemic obstacles that inhibit programmatic scale-up
t Inadequate political support for an energetic response
to hiv/aids
t The need for additional prevention tools
t Societal factors, such as stigma and gender inequality,
that impede effective prevention
Lack of Resources
Many of the limitations of existing strategies stem not
from deficiencies in the interventions themselves but
from a failure of political will. Global commitment to hiv
prevention remains timid in the face of escalating need,
and insufficient efforts have been directed toward the
social, economic, and physical conditions that increase
vulnerability to the virus.
Ninety-five percent of hiv infections are in the 
developing world, where resources are most limited.127
unaids estimates that $4.8 billion annually is needed to
implement an effective hiv prevention effort in low- and
middle-income countries, yet only about $800 million was
spent on hiv prevention interventions in those countries
in 2001128 and estimates indicate that approximately $1.2
billion will be spent in 2002.129 Due to inadequate funding,
current prevention efforts effectively reach only a small
fraction of those who are at risk of infection.130 Today
prevention strategies have only 10 to 20 percent global
coverage; even in some hard-hit countries in Africa, 
many teenagers don’t know how to protect themselves
from hiv infection; and fewer than 5 percent of hiv-
infected pregnant women worldwide receive appropriate
strategies to reduce mother-to-child transmission.
Even where grants are provided to developing coun-
tries to underwrite hiv prevention efforts, future funding
for these or related efforts is often uncertain. Many
grants are time-limited, meaning that countries are
unable to count on availability of grant funding beyond 
2 to 3 years. 
Scaling up to meet the global hiv prevention challenge
requires vastly greater resources and the maintenance of
such elevated expenditure levels for a decade or more. 
Systemic Obstacles to Effective 
hiv Prevention Scale-Up
Money alone, however, will not generate the appropriate
escalation in effective hiv prevention services. To equip
developing countries with the tools they require to scale
up to meet the hiv prevention challenge, assistance
should be provided to address a range of systemic or
political barriers to program implementation.
OBSTACLES
TO SCALING UP PROVEN 
PREVENTION STRATEGIES
Building Capacity
Although low-income countries have received extensive
hiv/aids assistance from donors since the epidemic’s
inception, there has been little investment in building
local capacity to sustain a long-term, high-level effort 
to prevent new infections. Capacity limitations in devel-
oping countries have been accentuated even further by
the epidemic itself, which has also eroded human capital.
Although many prevention programs could be largely
self-sustaining with sufficient local human capacity, 
the lack of attention to capacity-building has left many
countries heavily dependent on external assistance for
hiv prevention. 
Facing acute shortages in human capacity, low-income
countries lack the means to implement or scale up 
potentially effective programs. Personnel in developing
countries must urgently receive training in a range of
disciplines, and extensive technical assistance must be
provided to assist countries in developing systems
capable of delivery effective prevention programs.
Ensuring Access to Key Technologies
Inexpensive technologies that are available in industrial-
ized countries—male and female condoms, clean syringes,
hiv test kits, std treatments, substitution therapies for
drug addicts, arvs for short-course pmtct regimens—are
often unavailable in low and middle-income countries.
Mechanisms to purchase and transfer essential prevention
technologies should be substantially strengthened and
streamlined.
As demand for condoms has grown in response to
hiv prevention efforts, the world has begun to face a
possible shortage in high-quality, favorably priced
condoms. unaids says the current condom supply 
represents perhaps one-quarter of what the world would
need to mount an effective global prevention effort.131
Innovative public-private strategies to enhance industrial
capacity to manufacture condoms, as well as the develop-
ment of effective global purchasing mechanisms, are
needed to ensure that the condom supply will meet the
demand created by hiv prevention scale-up. 
Improving Access to Care
Limited access to care inhibits many crucial prevention
approaches. Individuals with little prospect of obtaining
effective care and treatment are likely to perceive little
incentive in learning their serostatus. Similarly, the lack
of health care access for hiv-infected mothers represents
a major barrier to scale-up of projects to prevent mother-
to-child transmission. For these reasons, effective expan-
sion of hiv prevention efforts will benefit from greater
access to care, treatment, and support. Treatment also
helps promote effective prevention by encouraging early
knowledge of serostatus, and helps reduce hiv/aids
stigma by underscoring the public value placed on the
health and well-being of people living with hiv/aids.
Improving Coordination and Strategic Planning
Ideally, donors and program planners would prioritize
especially cost-effective strategies, intervene at key 
points in the transition from a localized to a generalized
epidemic, and use a combination of proven strategies 
to contain emerging epidemics. Although international
donors presently underwrite a wide range of effective
prevention programs in developing countries, such 
initiatives are seldom part of a comprehensive national
plan to coordinate and maximize hiv prevention efforts.
While unaids and others have provided invaluable 
assistance to national authorities for the development 
of strategic aids plans, 1 in 4 countries have no national
aids strategy, including some in heavily-affected Africa
and many others with emerging epidemics. Fewer than
one-third of aids strategies in Asia, and less than half in
the Caribbean and Latin America, have been costed.132
Improving Surveillance Systems
Effective intervention to reduce an epidemic’s future
burden depends in large part on the quality and timeliness
of data regarding risk behaviors, rates of stds, and new hiv
infections in key populations. Unfortunately, in countries
where per capita spending on health services of any kind
amounts to $20 or less, little infrastructure typically exists
to collect such information. At best, health agencies 
may be able to gauge hiv prevalence in easy-to-access
populations, yet prevalence data may mask significant
changes in hiv incidence, and sentinel populations may
not be representative of the groups that will determine
the future course of the epidemic.133
Cost-effective strategies exist to improve surveillance
even in resource-poor countries134— and who, unaids,
cdc, and others have many initiatives to improve the
ability of low- and middle-income countries to monitor
the hiv/aids epidemic. Additional capacity-building is
needed in many countries, however, to enable national
authorities to collect the information needed to deploy




The Need for Enhanced Political Will
In every country where prevention has turned the tide
against hiv/aids, prevention efforts have received the
strong, vocal support of political leaders.
Political support has often been lacking in countries
most affected by hiv/aids. This, however, is changing, 
as leaders of low- and middle-income countries are now
placing strong priority on an effective response to
hiv/aids. The 2001 Abuja declaration reflected the 
determination of African leaders to wage an effective
fight against hiv/aids; in the Caribbean and Latin
America, leaders have banded together to promote 
cross-border collaboration to prevent the spread of hiv;
heads of government of the 10 asean member countries
pledged their leadership in the fight against hiv/aids in
November 2001; and leaders of the Commonwealth of
Independent States recently affirmed their support for 
an aggressive response to the emerging epidemic in that
region. The UN Declaration of Commitment on
hiv/aids, unanimously agreed to by 189 member nations
of the UN, outlines for the first time time-bound targets
for the reduction of new infections. And the new Global
Fund to Fight aids, Tuberculosis and Malaria represents
an important new avenue for funding of hiv prevention,
although funds pledged thus far are only a fraction of
what will be needed.
Although political support is growing for an energetic
response to the epidemic, renewed efforts are required in
many countries where hiv/aids is now emerging as a
major threat. Many countries in Central Asia and Eastern
Europe have no national plan to fight hiv/aids, and
some political leaders in the region remain in denial
about the threat posed by the disease. In Europe and the
U.S., where hiv prevention has not kept pace with
changes in the epidemic, a renewed commitment to
effective prevention is needed to prevent a resurgence 
of hiv/aids. Encouraging strong political support for
effective hiv prevention measures must become a 
high-priority global political issue and a point of
emphasis in diplomatic relations. 
The Need for New Prevention Tools
Although existing technologies (e.g., condoms, sterile
injection equipment, std treatments, pmtct) are highly
effective in reducing the risk of hiv transmission, 
additional hiv prevention technologies are badly needed.
Progress has been made in accelerating clinical research
on promising vaccine and microbicide candidates and
funding for such research has recently increased, but the
search for new and better prevention technologies still
preventive aids vaccine approaches 
currently in human testing
Principal Research Partners Vaccine Approach Subtype Ongoing Trials
iavi/University of Oxford; U.K. Medical Research hiv a (dna-mva) A Phase I/II: U.K., Kenya
Council; University of Nairobi; Kenya aids Vaccine 
Initiative; Imperial College of Science, Technology 
and Medicine; Cobra Therapeutic Ltd.; idt GmbH
Merck & Co. Inc. dna-Adeno B Phase I: U.S.
GlaxoSmithKline plc; hiv Vaccine Trials Network Gp120 nef-tat B Phase I: U.S.
U.S. National Institutes of Allergy and Infectious dna B Phase I: U.S.
Disease, Vaccine Research Center, Vical Inc.
Agence Nationale de Recherche sur le vih/sida Lipopeptides B Phase I: France
(France), Biovector Therapeutics sa
VaxGen Inc. aidsvax (gp120) B, E Phase III: U.S., Canada,
Netherlands, Thailand
VaxGen Inc., Aventis Pasteur sa, U.S. National alvac-aidsvax B, E Phase III: Thailand, scheduled
Institutes of Health, Walter Reed Army Institute (canarypox-gp120) to commence late 2002
of Research, Thailand Ministry of Health
Phase II finishing in Thailand, 
Haiti, Trinidad and Tobago, U.S.
Source: International aids Vaccine Initiative
confronts a range of obstacles. Most hiv research has
been geared to developed countries; unaids reports that
the study of hiv vaccines in Africa accounts for a mere
1.6 percent of all global aids research spending and that
Africa has been home to only two of the 30 vaccine trials
that have occurred since 1987.135
Scientific Challenges
On the scientific front, the search for a vaccine has been
slowed by uncertainty regarding the correlates of immu-
nity, questions regarding the importance of global viral
diversity on vaccination efforts, lack of a clearly appro-
priate animal model, and historic under-investment in
vaccines generally (and in hiv vaccines, specifically).136
More than 20 years since the first case of aids was
reported, only one vaccine candidate has entered Phase
iii trials, and numerous promising approaches to 
hiv vaccination are not being aggressively pursued. 
The global search for effective vaginal and rectal
microbicides faces challenges similar to those in the
vaccine field, including important scientific uncertainties,
methodological complexities in mounting clinical trials,
and limited public and private sector support for microbi-
cide r&d.137 Early trial results in the microbicide field
underscore the challenge of developing new, safe and
effective prevention technologies. Studies indicate that
nonoxynol 9, an early microbicide candidate, appears to
offer no protection against hiv and may, in fact, increase
the risk of transmission.138
In recent years, however, the microbicide field has
generated a rich pipeline of more than 50 candidate 
products that span a wide array of potential mechanisms
for preventing hiv transmission. Six of these products
are poised to begin large-scale effectiveness trials in 
the near future. In addition, new scientific approaches
are being used to develop novel methods that, with
appropriate resources, may ultimately become second-
and third-generation microbicides. 
Ensuring Access
Ensuring actual delivery of safe and effective vaccines or
microbicides as soon as they emerge may be an even
greater challenge than developing and testing such prod-
ucts. The International aids Vaccine Initiative explains: 
“Because vaccine development is a risky, privately
financed enterprise, vaccines are almost always initially
marketed exclusively in industrialized countries that have
the ability to pay full price. As years pass and the manu-
facturer’s production capacity and efficiency increase, the
price of the vaccine slowly declines. Eventually, the price
becomes sufficiently low to permit external aid donors
and selected developing country governments to
purchase the vaccine. Over time—a substantial period of
time—the vaccine is introduced piecemeal into poorer
countries, with many years passing before optimal 
vaccination levels are achieved.”139
To ensure meaningful access to new prevention 
technologies, the global community should develop
appropriate purchase mechanisms, enhance delivery
systems, ensure sufficient manufacturing capacity to
meet worldwide demand (which itself must be accurately
projected), and remove potential barriers stemming from
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summary of microbicide market evolution scenarios
First Generation Second Generation Third Generation
Expected launch 2007 2012 2017
Formulation vaginal only vaginal and rectal vaginal and rectal
Indications hiv, possibly other stds, hiv, herpes, gonorrhea hiv, herpes, gonorrhea
possibly contraceptive hpv, chlamydia; choice hpv, chlamydia; choice
of contraceptive or of contraceptive or
non-contraceptive non-contraceptive
hiv effectiveness 50 percent to 60 percent 70 percent to 90 percent 85 percent to 97 percent
Contraceptive effectiveness 75 percent to 85 percent 80 percent to 90 percent 90 percent to 97 percent
Use instructions w/condom or device stand alone stand alone
sales channel
Industrialized countries Prescription only Over the counter Over the counter
Developing countries Over the counter Over the counter Over the counter
Source: The Rockefeller Foundation
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the lack of harmony among the many national regulatory
authorities that must register new products. 
Although new prevention technologies are badly
needed, the world will continue to need an integrated
approach to prevention even after the emergence of new
vaccines and microbicides. Not only are first- and second-
generation prevention technologies likely to have some-
what limited efficacy, but even well-developed vaccination
campaigns usually require substantial time before
optimal vaccination levels are achieved. 
Societal Factors 
Although hiv transmission occurs through clearly defined
biological routes, hiv risk is profoundly affected by the
social environment in which human behavior occurs. To
maximize our ability to prevent new infections, science-
proven interventions should be supported with dramati-
cally greater efforts to reduce stigma, diminish growing
global economic inequities, and promote human rights. 
Reducing Stigma
hiv infection is often heavily stigmatized, abetted in 
large measure by its perceived association with sexual
promiscuity, homosexuality, and drug use.141 In many
countries, people with hiv are subject to violence and
social ostracism, as well as discrimination in employ-
ment, housing, and education. 
Individuals who fear being ridiculed, ostracized, or
subjected to violence will generally not seek vct or make
themselves available for hiv prevention services. In 
addition, a climate of stigma perpetuates the denial that
inhibits individual, community and national mobilization
to fight the disease.
Stigma is not immutable but rather can be alleviated
through strong political commitment, enactment of 
meaningful anti-discrimination laws, and greater public
awareness. The Declaration of Commitment on hiv/aids
agreed to by 189 member states of the United Nations 
obligates nations by 2003 to enact, strengthen or enforce
legal measures to eradicate hiv-related discrimination and
to protect the human rights of people living with hiv/aids.
Essential to the reduction of hiv-related stigma is the
visibility and openness of people living with hiv/aids.
Organizations of people with hiv/aids require both
financial support and technical assistance to enable 
them to undertake their courageous efforts to alter 
attitudes toward people living with the disease. 
Empowering Women and Girls 
Women’s lack of economic, social, legal and political
equality in many parts of the world seriously hinders hiv
prevention efforts. In particular, gender inequality often
makes it difficult for women to negotiate condom use and
safer sex with their sexual partners or to leave abusive rela-
tionships. Women’s social and economic disadvantages
An estimated 17,000 people with hiv/aids in the United
States (more than 90 percent of whom are men who
have sex with men (msm)) live in San Francisco. In
recent years, sexual risk behaviors among msm in the
city have increased, and evidence has emerged
suggesting an upturn in hiv incidence, as well.
In 2000, hiv-positive msm asked the city to initiate an
hiv prevention campaign targeting msm living with
hiv/aids. Using funding provided from the U.S. Centers
for Disease Control and Prevention, the San Francisco
Department of Public Health decided to develop a
comprehensive prevention effort targeting msm living
with hiv/aids. One component of the program was a
social marketing campaign entitled “hiv Stops with Me.”
msm living with hiv were actively involved in the
conception and development of the project, which
included television commercials, newspaper advertise-
ments, postcards, and an internet campaign. hiv-posi-
tive men also served as spokespeople for the campaign,
which sought to reduce the number of new infections
and to increase the sense of community among msm
and transgender individuals living with hiv/aids.
An evaluation of the project found that 19 percent of
hiv-positive msm surveyed said they were more likely
after seeing the campaign to use a condom with a
partner who is uninfected or has unknown serostatus. 
A similar percentage indicated they were more likely to
disclose their hiv status to a partner before having sex.
Nearly 1 in 4 of those surveyed said the campaign had
increased their belief in the responsibility of hiv-positive
individuals to help keep their partners uninfected.140
involving people with hiv/aids in hiv
prevention efforts
for u.s. men who have sex with men
also make them less likely to obtain needed services, such
as vct, std screening and treatment, reproductive health
services, and hiv prevention counseling. 
Strengthened microfinance programs, enhancement
of women’s opportunities to generate income, universal
education for girls and initiatives to keep girls in school,
and enactment and enforcement of laws to prevent
violence and other forms of abuse against women are
critically necessary to reduce women’s vulnerability to
hiv infection. 
In addition, young people, most typically girls, are
often forced (physically or by economic circumstances) to
engage in sex work. They frequently lack the social power
to protect themselves from violence, hiv infection and
other stds. Effective hiv prevention requires the pursuit
of multiple strategies to reduce vulnerability to sexual
coercion, including enhanced law enforcement, universal
education, and international support for the framework
set forth in the Yokohama Global Commitment adopted
in 2001 at the 2nd World Congress Against Commercial
Exploitation of Children.
At the same time that countries pursue strategies to
empower women and girls, they should also target men
and boys with efforts designed to alter their own attitudes
about women. In many countries, prevailing gender rela-
tions, as reflected in the systematic disempowerment of
women, are also placing men at greater risk of infection. 
Reducing Risk in Emergency Situations
Civil strife, natural disasters and other emergencies have
driven an estimated 40 million people from their homes,
significantly increasing hiv vulnerability. According to
unaids: “People displaced by conflict and other emergen-
cies live through chaotic conditions, during which
hiv/aids is not likely to be seen as a priority. Yet hiv
spreads fastest in conditions of poverty, powerlessness
and social instability, the conditions that are at their
extreme in complex emergencies.”142 In particular, the
chaos and poverty experienced by refugees and internally
displaced people often coerce individuals into using sex
to obtain basic needs such as food, shelter and personal
security.143 Effective prevention requires international
efforts to prevent or ameliorate instances of conflict or
civil unrest, as well as enhanced health education efforts




Declaration of Commitment on
hiv/aids
UN Special Session on hiv/aids, June 2001
t Ensure by 2005 access in all countries to a broad
array of prevention programs.
t Ensure by 2005 that at least 90 percent of young
people (15 to 24)—and 95 percent of such people by
2010—have meaningful access to the information,
education and services needed to protect themselves
from hiv infection.
t Reduce by 2005 the rate of hiv infection among
young people by 25 percent, and reach this target
globally by 2010.
t Reduce the proportion of infants born with hiv by 20
percent by 2005 and by 50 percent by 2010.
t Strengthen hiv prevention efforts by enacting or
strengthening anti-discrimination and other human
rights laws, by empowering women, and by taking
steps to reduce the vulnerability of key populations
to hiv.
verwhelming scientific evidence and more than
20 years’ experience clearly demonstrate how
to prevent hiv transmission. The challenge
currently facing the world is taking proven
prevention strategies to scale, reaching those in need, and
reversing the epidemic’s projected course. Scaling up to
meet the global hiv prevention challenge requires:
t Significantly greater resources
t Increasing local capacity and expanding proven 
prevention strategies
t Vocal political support
t Better strategic planning
t Ensuring access to existing prevention tools
t Accelerating research into new prevention 
technologies
t Confronting social factors that facilitate the spread of hiv
Substantially Increase and Sustain 
Prevention Funding
Increase international resources. Annual investment in
hiv prevention in low- and middle-income countries
should quadruple by 2004—from approximately $1.2
billion in 2002 to $4.8 billion in 2004, as called for by
unaids.
t After 2004, global expenditure for hiv prevention
should be sustained at this level well into the next
decade in order to reverse the aids epidemic. 
t Although unprecedented, such sums are entirely
achievable, amounting to approximately $5 annually
for every person living in the U.S. and Europe.
Enable countries to prioritize resources for hiv/aids.
Every effort should be made to give countries the ability
to prioritize resources for hiv/aids, especially resource-
poor countries financially encumbered by debt. 
t Urgently needed resources for social services and hiv
prevention cannot be appropriately harnessed in the
face of high debt burdens. 
t Donor nations should provide new targeted funding to
the World Bank and unaids to assist heavily-indebted
countries to integrate hiv/aids into the poverty reduc-
tion strategies required to ease debt burden.
Build Capacity and Scale Up 
Proven Prevention Strategies 
Increase local capacity. Resources should be devoted 
to training local personnel and providing necessary 
technology so that affected countries can rapidly and
sustainably scale up prevention programs. 
t Due to limited support for capacity-building, a
shortage in critical skills, and the loss of personnel due
to the epidemic itself, many low-income countries lack
the human capacity to scale up effective interventions. 
t Developed and developing countries should work
together to create a costed, comprehensive plan to
enhance sustainable human capacity for rapid preven-
tion program scale-up.
t Professionals, providers and academic experts with
relevant expertise—drawn from both developed and
developing countries that have achieved success in
reducing new infections—should provide training in
all areas relevant to hiv prevention, including labora-
tory skills, surveillance and epidemiology, std control,
hiv clinical practice, counseling, social marketing, and
implementation of needle and syringe projects. 
t Donor nations should finance this effort, which should
be carefully coordinated with unaids, who, unicef,
and undcp.
Expand existing prevention strategies. With additional
resources and access to training and prevention tools,
countries should rapidly bring to scale key prevention
interventions that can work together to achieve
maximum prevention impact.
t In particular, countries should scale up vct; mass
media campaigns; condom distribution, promotion
and social marketing; blood screening; school-based
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programs; programs for out-of-school youth; workplace
programs; std treatment; and peer counselors for
vulnerable populations, such as sex workers, men who
have sex with men (msm), and injection drug users
(idus). 
t Particularly high priority should be given to scale-up 
of programs that prevent transmission in vulnerable
populations, including young people, sex workers and
their clients, msm, and idus.
Encourage Vocal Political Leadership
Make hiv/aids a priority. Political leaders should speak
often and forcefully about the importance of hiv preven-
tion, support policies that effectively fight aids and
stigma, and make hiv/aids a permanent agenda item at
important global and regional political gatherings.
t hiv/aids should become a permanent agenda item at
important international gatherings, including the g-8
summit, the World Economic Forum, regular sessions
of the UN General Assembly and Security Council,
other major UN gatherings such as the World Health
Assembly, and regional political gatherings. 
t Political leaders should become vocal advocates of
national hiv prevention efforts. This is especially
important in many countries with emerging
epidemics, where aids has not yet become an urgent
item on national agendas. 
t Political leaders should avoid embracing strategies that
lack scientific support, such as mandatory hiv testing,
isolation of people with hiv/aids, or other coercive
measures. 
Use Prevention Resources More Strategically 
Improve tracking of hiv/aids. Developing countries
should receive training and financial and technical assis-
tance to enhance their ability to track hiv/aids and plan
prevention interventions accordingly. 
t Effective surveillance is the cornerstone of strategic
health planning. Monitoring of hiv infections and 
risk behaviors not only highlights opportunities for
intervention but also provides quick feedback on the
success of prevention strategies. 
t Donor nations should provide targeted funding to who
to help developing countries strengthen their public
health surveillance systems.
t Particular attention should be given to the transfer of
important epidemiologic tools, including cost-effective
strategies and technologies that assist in clarifying
emerging infection trends.
Ensure strategic planning. By 2003, every country should
have a strategic hiv prevention plan. 
t Nearly one in four low- and middle-income countries
has no strategic plan for aids, and those that have
strategies often have no plans for implementation. 
t unaids should continue its important assistance to
countries in the development of strategic plans. 
t Priority should be given to regions with emerging
epidemics, such as Central Asia and Eastern Europe,
where many countries currently lack strategic aids
plans.
t Development or revision of strategic plans should,
where possible, be informed by comprehensive
epidemic “maps” of each national epidemic. Donor
nations should provide expertise to assist countries in
analyzing all available data (e.g., hiv/aids surveillance,
std surveillance, population surveys, etc.) to identify
key target populations, epidemic “hot spots,” potential
epidemiologic bridges to other populations, and factors
that may be accelerating transmission. Experts should
assist countries in identifying cost-effective strategies
that address key factors revealed in this epidemic
“mapping” process. 
Coordinate funds. By 2003, all low-income countries
should convene annual “donor roundtables,” bringing
together all key funders to measure available resources,
identify resource gaps, and enhance program coordination. 
t With assistance from who/unaids, roundtables should
use the Country Coordination Mechanisms (ccms)
mandated by the Global Fund to Fight aids, Tubercu-
losis and Malaria (gfatm), or the expanded UN Theme
Groups on hiv/aids where ccms do not exist. Roundta-
bles should identify resource gaps, improve coordina-
tion, and inform national strategic prevention planning.
Expand Access to Key Prevention Tools
Ensure an adequate supply of prevention tools. Donor
nations should ensure an adequate global supply of 
high-quality hiv prevention tools (e.g., condoms and hiv
test kits) for use in developing countries.
t Donor nations should collaborate with who, unaids,
World Bank, the World Economic Forum, unicef, and
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others to develop by the end of 2002 a comprehensive
public-private strategy to ensure a sufficient global
supply of key prevention commodities (e.g., male 
and female condoms, hiv test kits, etc.). Tax credits,
subsidies, or direct public sector ownership of new
manufacturing facilities should be considered. 
t In collaboration with who, unaids, unicef, and the
World Bank, the Global Fund to Fight aids, Tubercu-
losis and Malaria (gfatm) should identify by the end of
2002 feasible, efficient purchase mechanisms for all
key hiv prevention commodities (e.g., hiv test kits,
std diagnostics and treatments, arvs, etc.). Where
possible, strong preference should be given to existing
channels for the purchase of key commodities. 
t Purchase mechanisms should include capacity to
ensure that commodities bought for use in developing
countries are of the highest quality. 
t gfatm should work with donor nations to provide
targeted funding to strengthen purchase mechanisms
or, where necessary, to establish such mechanisms.
Increase access to treatment. Access to hiv treatments,
including arvs, should be dramatically expanded—both
to reduce hiv-related sickness and death and to buttress
hiv prevention efforts by reducing stigma and encour-
aging knowledge of hiv status. 
t Donor nations, developing countries and unaids/who
should work together to meet who’s goal of ensuring
the provision of arvs to at least 3 million people with
hiv/aids by 2005, or an estimated 50 percent of all
who need them. 
t Strategies to facilitate greater access to arvs should
address the cost of the drugs, training needs for clin-
ical staff, access to technologies to monitor patients,
and other infrastructure needs. 
Accelerate Research Into New 
Prevention Technologies
Increase funding. Public sector funding for research and
development should increase by $1 billion for hiv/aids
vaccines and by $1 billion for microbicides by 2007, and
grow substantially for other new prevention technologies. 
t Funding should support both basic science research
and efforts to accelerate research and development on
potential candidate vaccines and microbicides.
t Additional public sector support is also needed for
research into other new hiv prevention technologies,
such as female-controlled barrier methods. 
t Provide private sector incentives. Donor nations
should provide financial incentives to private compa-
nies to increase their investment in research and devel-
opment related to hiv/aids vaccines, microbicides, and
other new prevention technologies. 
t In particular, donor nations should consider enactment
of tax incentives for companies that invest in such r&d. 
t Because early candidates are often developed by small
biotech companies, such laws should permit tax credits
to be passed along to any subsequent purchaser of
such companies. 
Coordinate efforts. Industry, donors, multilateral 
agencies, and ngos should work together on an ongoing
basis to identify obstacles to acceleration of hiv vaccine
and microbicide r&d, and agree on approaches to 
overcoming such obstacles. 
t Goals for such collaboration should include enhance-
ment of clinical trial infrastructure; joint assessment of
potential clinical trial cohorts; identification of poten-
tially promising scientific approaches that are not
presently being pursued; and agreement on key mile-
stones in the search for safe and effective prevention
technologies. 
Ensure access. Donor nations, developing countries, and
multilateral agencies should immediately develop and
implement strategies to ensure future access to hiv/aids
vaccines and microbicides. 
t By its summit meeting in 2003, the g-8 should publicly
commit that accessible and adequately funded public
sector mechanisms will exist to ensure the purchase
and distribution of safe and effective vaccines and
microbicides as soon as such products are available. 
t Funding for enhancement of delivery systems relevant 
to vaccines or microbicides should be available from
bilateral donors, the World Bank, and the gfatm, with
every effort made to ensure that such enhancements
have immediate benefits to developing countries by
focusing on existing underdeveloped infrastructure (e.g.,
health care sites, family planning sites, schools, etc.).
Confront Social Factors that 
Facilitate the Spread of hiv 
Fight stigma. Countries should enact hiv-specific human
rights protections, and people living with hiv/aids
should be involved at every stage in the planning and
implementation of hiv prevention programs.
t Countries should implement enforceable policies to
promote and protect the human rights of populations
that are especially vulnerable to hiv/aids, including
sex workers, idus, and men who have sex with men. 
t Countries should also enact strong measures to
prevent discrimination against people with hiv/aids,
as respect for people with hiv/aids is essential to
reduce the stigma associated with the disease.
t In countries where hiv prevention efforts have
succeeded, people living with hiv/aids have made
major contributions to hiv prevention efforts.
Reduce poverty. Accelerated efforts are needed to reduce
the poverty that facilitates hiv transmission and worsens
the social and economic impact of hiv infection. 
t Donor nations should, consistent with the Declaration
of Commitment on hiv/aids adopted at the UN
Special Session on the epidemic in 2001, ensure that
official development assistance equals at least 0.7
percent of gnp.
t In addition to increasing direct assistance to devel-
oping countries, donor nations should actively explore
additional strategies to reduce poverty, such as
promoting trade with developing countries and
increasing educational opportunities.
Empower women. Global efforts to empower women
must be dramatically expanded. 
t Donor nations must significantly increase support for
microfinance programs, girls’ education initiatives,
mechanisms to enforce laws against sexual trafficking
and commercial exploitation of children, and other
strategies to increase the economic, legal, political, and
social power of women. 
t Countries should enact enforceable laws ensuring
women’s full human rights.
t Efforts to empower women should also explicitly
address male attitudes toward sexual and gender 
relations, encouraging men to play a more active role
in preventing hiv transmission. 
t Increased efforts must be made to channel debt relief
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